Sponsor: Atara Biotherapeutics, Inc.
Sponsor Study ID: ATA129-EBV-302
Study Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein Barr Virus Associated Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
CTO #: 102889
NCT Number: NCT03394365
Phase: III
Protocol Type: Treatment
Age Group: Both
Disease Sites: Kidney, Liver, Lung, Pancreas, Small Intestine
Study Objectives: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)